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Antimicrobial resistance is an evolving issue, and new therapeutics are needed to treat infections caused by the pathogens of biodefense interest and those that are considered to be of public health concern. It is important that new antimicrobials are evaluated under conditions that model those encountered within the environment of a host, including the low-pH environment of the cell (the phagolysosome) that is particularly relevant to intracellular pathogens and infected body sites. It has been shown previously that the activity of certain classes of antibiotics (including fluoroquinolones) can be affected by a reduction in pH ([@B1][@B2][@B4]). Finafloxacin is a fluoroquinolone derivative with an 8-cyano substituent and 7-pyrrolo-oxazinyl moiety that is being developed for the treatment of urinary tract infections in hospitalized patients ([@B5], [@B6]). This modification has conferred activity in low-pH environments, which has resulted in superior *in vitro* activity against a range of organisms, including Staphylococcus aureus and Acinetobacter baumannii ([@B7], [@B8]).

The availability of formulations of finafloxacin that can be delivered orally and systemically makes finafloxacin a worthy alternative for the treatment of a range of infections. In addition to good safety and efficacy data obtained in patients suffering from complicated urinary tract infections and pyelonephritis, previous studies have also demonstrated efficacy against the biothreat agents Burkholderia pseudomallei and Francisella tularensis *in vitro* and *in vivo* ([@B6], [@B9][@B10][@B11]). The aim of this study was to further evaluate the *in vitro* activity of finafloxacin against larger strain panels of biodefense pathogens.

Antibiotic susceptibility was determined at pH 5 and pH 7 for B. pseudomallei (*n* = 10), Burkholderia mallei (*n* = 10), F. tularensis (*n* = 10), Bacillus anthracis (*n* = 10), and Yersinia pestis (*n* = 10), held at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) ([Table 1](#T1){ref-type="table"}). In addition, a B. pseudomallei strain panel (*n* = 11) provided by the Biomedical Advanced Research and Development Authority (BARDA) was screened ([Table 1](#T1){ref-type="table"}) ([@B12]). These assays were performed under biosafety level 3 (BSL3) conditions. Antibiotic susceptibility was reported as the MIC~50~ or MIC~90~, defined as the lowest concentration of the antibiotic at which the growth of 50% or 90% of the isolates, respectively, were inhibited.

###### 

Panel of bacterial strains evaluated

  Organism          Strain[^*a*^](#T1F1){ref-type="table-fn"}   Origin                Source
  ----------------- ------------------------------------------- --------------------- -----------
  B. pseudomallei   316c                                        Thailand              Human
  E203              Thailand                                    Unknown               
  NCTC4845          Singapore                                   Monkey                
  STW115-2          Thailand                                    Water                 
  STW199-2          Thailand                                    Water                 
  E8                Thailand NE                                 Soil                  
  P52237            Vietnam                                     Unknown               
  WRAIR1188         Malaysia                                    Human                 
  K96243            Thailand                                    Human                 
  1026b             Thailand                                    Human                 
  K96243\*          Thailand                                    Human                 
  1026b\*           Thailand                                    Human                 
  HBPUB10134A\*     Thailand                                    Human                 
  HBPUB10303A\*     Thailand                                    Human                 
  1106a\*           Thailand                                    Human                 
  MSHR 305\*        Australia                                   Human                 
  MSHR 668\*        Australia                                   Human                 
  MSHR 5855\*       Australia                                   Human                 
  MSHR 5848\*       Australia                                   Human                 
  MSHR 5858\*       Thailand                                    Human                 
  406e\*            Thailand                                    Human                 
  F. tularensis     LVS                                         Former Soviet Union   Water rat
  OR01-1807         USA                                         Unknown               
  FRAN003           USA                                         Unknown               
  FRAN005           USA                                         Unknown               
  FRAN006           USA                                         Unknown               
  FRAN007           USA                                         Unknown               
  FRAN012           USA                                         Unknown               
  FRAN013           USA                                         Unknown               
  FRAN016           USA                                         Unknown               
  SCHUS4-1          USA                                         Human                 
  B. anthracis      Vollum1B                                    USA                   Bovine
  Sterne            South Africa                                Bovine                
  Ames              USA                                         Bovine                
  K1938             Indonesia                                   Unknown               
  K5926             India                                       Unknown               
  K7038             South Korea                                 Unknown               
  SK57              England                                     Unknown               
  K7978             Namibia                                     Unknown               
  Africa33          South Africa                                Unknown               
  K8091             Norway                                      Unknown               
  B. mallei         GB3 (ATCC 120)                              UK                    Unknown
  GB4               Turkey                                      Human                 
  GB5               Hungary                                     Unknown               
  GB6               Turkey                                      Human                 
  GB7               Turkey                                      Unknown               
  GB8 (China7)      Burma                                       Human                 
  GB9               India                                       Mule                  
  GB10              India                                       Horse                 
  GB11              China                                       Horse                 
  GB12              Hungary                                     Unknown               
  Y. pestis         CO92                                        USA                   Human
  C12               USA                                         Human                 
  antiqua           Congo                                       Human                 
  pestoidesB        Former Soviet Union                         Human                 
  pestoides Fmp1    Former Soviet Union                         Human                 
  Yeo154            Japan                                       Human                 
  Angola            Angola                                      Human                 
  Java9             Indonesia                                   Human                 
  M111(74)          Madagascar                                  Human                 
  LaPaz             Bolivia                                     Human                 
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Strains with an asterisk belong to the BARDA strain panel. All other strains were obtained from the USAMRIID Unified Culture Collection (UCC), Frederick, MD, USA.

Finafloxacin was supplied by MerLion Pharmaceuticals GmbH, and all other antibiotics were sourced from the U.S. Pharmacopeia, Selleckchem, or Sigma. Broth microdilution assays were performed as detailed by the Clinical and Laboratory Standards Institute (CLSI) ([@B13]), with the exception of a medium supplement (2%), IsoVitaleX (Becton, Dickinson), used to support the growth of F. tularensis. The activity of finafloxacin was determined at pH 5 and pH 7 (if the bacterial species was able to be cultured) and the MICs determined.

At pH 5, the MICs for B. pseudomallei ranged from 0.12 to 2 μg/ml, 16 to 64 μg/ml, and 4 to 64 μg/ml for finafloxacin, ciprofloxacin (CIP), and ceftazidime (CAZ), respectively, demonstrating the superior *in vitro* activity of finafloxacin at low pH. Although it is difficult to make comparisons between the efficacies of antibiotics simply by MIC, these values are lower than those determined for another fluoroquinolone, CIP, and a component of the treatment for B. pseudomallei infections in humans (CAZ) ([Fig. 1A](#F1){ref-type="fig"}). At neutral pH, finafloxacin demonstrated a level of activity (0.5 to 8 μg/ml) similar to those observed with CIP (1 to 4 μg/ml) and CAZ (0.5 to 32 μg/ml) ([Fig. 1B](#F1){ref-type="fig"}).

![Cumulative MICs determined for a panel of B. pseudomallei strains for finafloxacin (*n* = 21), ciprofloxacin (*n* = 11), and ceftazidime (*n* = 11) at pH 5 (A) and pH 7 (B).](AAC.01470-19-f0001){#F1}

A similar trend was observed with the other pathogens of biodefense interest. Finafloxacin had superior activity at pH 5 for B. anthracis, B. mallei, and Y. pestis compared to either CIP or azithromycin (AZM) (an antibiotic used for the treatment of B. mallei infection in humans and as a control in the *in vitro* assays) ([Table 2](#T2){ref-type="table"}). Unfortunately, only two strains of F. tularensis could be cultured in this low-pH environment; therefore, the MIC~50~ and MIC~90~ at pH 5 could not be determined. The most striking difference was observed for B. mallei. Finafloxacin had 9-fold and 7-fold improved activity over that of AZM against a panel of these strains (MIC~50~, 0.12 μg/ml compared to \>64 μg/ml; MIC~90~, 0.5 μg/ml compared to \>64 μg/ml) when performed at pH 5 ([Table 2](#T2){ref-type="table"}). At pH 7, finafloxacin demonstrated activity similar to those of the comparator antibiotics, with MIC~50~ and MIC~90~ of 0.5 μg/ml (at both pHs) for B. mallei and 0.06 μg/ml and 0.12 μg/ml for B. anthracis, respectively ([Table 2](#T2){ref-type="table"}).

###### 

MIC~50~, MIC~90~, and MIC range values determined for panels of the biothreat pathogens

  Species         MIC (μg/ml) by pH[^*a*^](#T2F1){ref-type="table-fn"}                                                                                                                                                              
  --------------- ------------------------------------------------------ ------ ------ ------- ------- ------ ------- ------ ------ ------- ------ ----- --------------- -------------- ----------- --------------- --------------- -------------
  B. anthracis    ≤0.03                                                  0.06   ND     0.06    0.03    ND     ≤0.03   0.06   ND     0.12    0.03   ND    ≤0.03 to 0.06   0.03 to 0.06   ND          0.06 to 0.12    0.03 to 0.06    ND
  B. mallei       0.12                                                   ND     \>64   0.5     ND      0.25   0.5     ND     \>64   0.5     ND     0.5   ≤0.03 to 0.5    ND             4 to \>64   ≤0.03 to 0.5    ND              0.06 to 0.5
  Y. pestis       ≤0.03                                                  0.5    ND     ≤0.03   0.015   ND     ≤0.03   1      ND     0.06    0.03   ND    ≤0.03           0.12 to 1      ND          ≤0.03 to 0.12   0.008 to 0.03   ND
  F. tularensis   ND                                                     ND     ND     ≤0.03   0.015   ND     ND      ND     ND     ≤0.03   0.03   ND    ND              ND             ND          ≤0.03           0.008 to 0.25   ND
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ND, not determined.

The data set detailed in these studies demonstrates that finafloxacin has activity under both acidic and neutral conditions, with enhanced activity of finafloxacin in low-pH environments, where other antibiotics (including ciprofloxacin) have reduced activity. This has been demonstrated for all of the biodefense pathogens of interest and is in agreement with data generated by other groups ([@B7], [@B8], [@B10], [@B11]). The improved activity of finafloxacin compared to that of ciprofloxacin (a typical treatment for infections caused by B. anthracis, Y. pestis, and F. tularensis) further highlights the importance of evaluating therapies under conditions considered to be more like those encountered within a host and identifies finafloxacin as a novel broad-spectrum fluoroquinolone that could be used for prophylaxis or treatment following exposure to a range of pathogens.

Of particular interest is the activity of finafloxacin against the Burkholderia species evaluated. It has been demonstrated previously that fluoroquinolones are not effective as treatment for melioidosis in humans mainly due to B. pseudomallei possessing resistance mechanisms, including efflux pumps ([@B14][@B15][@B17]). The results detailed in this communication suggest that finafloxacin is not affected by the efflux pumps in B. pseudomallei that confer resistance to other fluoroquinolones, possibly due to the effect of the modified chemical structure ([@B7], [@B10], [@B18]). The promising data generated for B. mallei suggest that finafloxacin is a potential alternative for the treatment of infection caused by this organism.

Finafloxacin appears to have a wider spectrum of activity than the other fluoroquinolones and has the potential to be used to treat infections caused by all of the biothreat pathogens evaluated ([@B19]). It has also been shown to be safe and well tolerated in clinical trials ([@B6]). These encouraging *in vitro* findings warrant further investigation of finafloxacin which would determine whether this activity translates into comparable protection against all of these pathogens *in vivo*.
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